Lanzalone, Silvana
Pfizer (Italy)
2 papers on CoChat
Most cited papers
- Verified
Phase Ib Study of Crizotinib plus Pembrolizumab in Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer with ALK Translocation
Patel, S. P., Pakkala, S., Pennell, N. A., Reckamp, K. L., Lanzalone, S., Polli, A., Tarazi, J., & Robert-Vizcarrondo, F. (2020) · The Oncologist
Lung Cancer Treatments and MutationsCancer Immunotherapy and Biomarkers
Cited by 34
- Verified
Abstract CT071: Talazoparib (TALA) in germline BRCA1/2 (g BRCA1/2)-mutated human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC): Final overall survival (OS) results from randomized Phase 3 EMBRACA trial
Litton, J. K., Hurvitz, S. A., Mina, L. A., Rugo, H. S., Lee, K.-H., Gonçalves, A., Diab, S., Woodward, N., Goodwin, A., Yerushalmi, R., et al. (2020) · Cancer Research
PARP inhibition in cancer therapyBRCA gene mutations in cancer
Cited by 10
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free